Payment overview · 2025
General Payments
$549.70
29 reported records · 16 companies
Healthcare provider profile · identity verified
Kyle Christopher Farley, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · NORTH CANTON, OH · NPI 1083008874
Verified facts
What the public records show
CMS Open Payments records show Kyle Christopher Farley, D.O. received $549.70 in general payments during 2025 across 29 reported records.
Novo Nordisk Inc accounted for 27.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Jardiance, Ozempic, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $153.44 | 27.9% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $73.52 | 13.4% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $49.65 | 9.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.53 | 6.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $29.23 | 5.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.17 | 5.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.28 | 5.0% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.29 | 4.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.75 | 3.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.61 | 3.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.21 | 3.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.16 | 2.9% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $15.66 | 2.9% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $13.94 | 2.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.72 | 2.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.54 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $549.70 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $138.89 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $73.52 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $49.65 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.53 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.53 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $29.23 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $27.28 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $26.29 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $20.75 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.83 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.16 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.55 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $13.58 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 82 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 51 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 170 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 115 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
70 | 18 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
51 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
82 | 82 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
115 | 98 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
170 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
51 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 675 | 163 |
| Lisinopril | Lisinopril | 457 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 368 | 99 |
| Losartan Potassium | Losartan Potassium | 347 | 95 |
| Omeprazole | Omeprazole | 304 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 284 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 236 | 71 |
| Simvastatin | Simvastatin | 211 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 203 | 58 |
| Metformin Hcl Er | Metformin Hcl | 199 | 43 |
| Gabapentin | Gabapentin | 192 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 191 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 174 | 56 |
| Jardiance | Empagliflozin | 170 | 33 |
| Metformin Hcl | Metformin Hcl | 160 | 45 |
| Meloxicam | Meloxicam | 143 | 59 |
| Montelukast Sodium | Montelukast Sodium | 137 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 126 | 45 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 115 | 98 |
| Metoprolol Tartrate | Metoprolol Tartrate | 113 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 105 | 33 |
| Potassium Chloride | Potassium Chloride | 99 | 24 |
| Trazodone Hcl | Trazodone Hcl | 97 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 28 |
| Allopurinol | Allopurinol | 88 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 86 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 85 | 20 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 82 | 82 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 75 | 13 |
| Sertraline Hcl | Sertraline Hcl | 74 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 44 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 71 | 71 |
| Furosemide | Furosemide | 70 | 23 |
| Synthroid | Levothyroxine Sodium | 70 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 29 |
| Enalapril Maleate | Enalapril Maleate | 63 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 16 |
| Glimepiride | Glimepiride | 60 | 17 |
| Carvedilol | Carvedilol | 59 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 20 |
| Tramadol Hcl | Tramadol Hcl | 54 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 14 |
| Eliquis | Apixaban | 51 | 18 |
| Celecoxib | Celecoxib | 49 | suppressed |
| Ezetimibe | Ezetimibe | 49 | 13 |
| Famotidine | Famotidine | 49 | 14 |
| Lovastatin | Lovastatin | 48 | 14 |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Lansoprazole | Lansoprazole | 45 | suppressed |
| Prednisone | Prednisone | 45 | 39 |
| Warfarin Sodium | Warfarin Sodium | 45 | 13 |
| Bupropion Xl | Bupropion Hcl | 44 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 38 |
| Alprazolam | Alprazolam | 41 | 11 |
| Ozempic | Semaglutide | 41 | suppressed |
| Azithromycin | Azithromycin | 39 | 37 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 31 |
| Diazepam | Diazepam | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 29 | suppressed |
| Trospium Chloride | Trospium Chloride | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 19 |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 16 |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 16 |
| Ramipril | Ramipril | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Indapamide | Indapamide | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $549.70 · 29 records | Novo Nordisk Inc | ABRYSVO, AREXVY, Auvelity, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 3, Fibroscan, Flexitouch Plus, INGREZZA, JARDIANCE, MOUNJARO, Nimbl, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, UBRELVY, VOQUEZNA, Wegovy, XIFAXAN, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error